Canlyniadau Chwilio - Matilde Saggese

  • Dangos 1 - 9 canlyniadau o 9
Mireinio'r Canlyniadau
  1. 1
    Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours

    Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours gan Catherine Van Poznak, Simon S. Cross, Matilde Saggese, Clifford A. Hudis, Katherine S. Panageas, Larry Norton, Rob Coleman, Ingunn Holen

    Cyhoeddwyd 2006
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Interleukin-10 Expression in Macrophages during Phagocytosis of Apoptotic Cells Is Mediated by Homeodomain Proteins Pbx1 and Prep-1

    Interleukin-10 Expression in Macrophages during Phagocytosis of Apoptotic Cells Is Mediated by Homeodomain Proteins Pbx1 and Prep-1 gan Elaine Y. Chung, Jianguo Liu, Yoichiro Homma, Yunhua Zhang, Andrea Brendolan, Matilde Saggese, Jihong Han, Roy L. Silverstein, Licia Selleri, Xiaojing Ma

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

    Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA gan Helen Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, Manuel Cobo, Thomas John, Craig Barker, Alexander Kohlmann, Alexander Todd, Matilde Saggese, Juliann Chmielecki, Aleksandra Markovets, Marietta Scott, Suresh S. Ramalingam

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

    Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study gan Ying Cheng, Yong He, Wěi Li, Helong Zhang, Qing Zhou, Buhai Wang, Chunling Liu, Andrew Walding, Matilde Saggese, Xiangning Huang, Minhao Fan, Jia Wang, Suresh S. Ramalingam

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

    A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer gan Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier García-Corbacho, Antoîne Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura, James Spicer

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Congenital Asplenia in Mice and Humans with Mutations in a Pbx/Nkx2-5/p15 Module

    Congenital Asplenia in Mice and Humans with Mutations in a Pbx/Nkx2-5/p15 Module gan Matthew Koss, Alexandre Bolze, Andrea Brendolan, Matilde Saggese, Terence D. Capellini, Ekaterina Bojilova, Bertrand Boisson, Owen W.J. Prall, David A. Elliott, Mark J. Solloway, Elisa Lenti, Chisa Hidaka, Ching-Pin Chang, Nizar Mahlaoui, Richard P. Harvey, Jean‐Laurent Casanova, Licia Selleri

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

    Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset gan Byoung Chul Cho, B. Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Virote Sriuranpong, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, Jong Seok Lee, Helen Mann, Matilde Saggese, Thanyanan Reungwetwattana, Suresh S. Ramalingam, Yuichiro Ohe

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

    Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Adv... gan Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong, Johan Vansteenkiste, Fumio Imamura, Jong Seok Lee, Yong‐Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng, Naoyuki Nogami, Eun Kyung Cho, Wu‐Chou Su, Guili Zhang, Xiangning Huang, Xiaocheng Li-Sucholeiki, Brian Lentrichia, Simon Dearden, Suzanne Jenkins, Matilde Saggese, Yuri Rukazenkov, Suresh S. Ramalingam

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLC

    Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLC gan Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: